The emphasis is on rigorous, academically informed clinical trials, capitalizing on our extensive clinical and academic facilities. This allows us to undertake a broad range of trials, from first-in-patient studies (i.e. phase 1B) all the way up to large national and international multicenter clinical trials (phase 2A/B and 3). Of importance, our trials are supported by state-of-the-art brain imaging and liquid biomarker outcome measures.
The IAO teams focuses in particular on clinical development of innovative therapies in Alzheimer disease, Multiple Sclerosis, Parkinson’s disease, neuroinflammation, stroke, and neurosurgical and interventional procedures (including deep-brain stimulation and acute treatment of stroke), but also on biomarkers to refine treatment strategies. In addition, we are currently shaping our translational research service offering in the field of Psychiatry.
